Lv31
290 积分 2023-04-28 加入
Exposure–Response Analysis of Repotrectinib to Support the Dose Recommendation for Patients With ROS1‐Positive NSCLC or NTRK‐Positive Solid Tumors
4小时前
已完结
Exploring 4th generation EGFR inhibitors: A review of clinical outcomes and structural binding insights
10天前
已完结
A clinical review on third and fourth generation EGFR tyrosine kinase inhibitors for the treatment of non-small cell lung cancer
10天前
已完结
Mechanisms of osimertinib resistance and emerging treatment options
14天前
已完结
Navigating the landscape of EGFR TKI resistance in EGFR-mutant NSCLC — mechanisms and evolving treatment approaches
15天前
已完结
Case Definition and Phenotype Standardization in Drug-Induced Liver Injury
1个月前
已完结
First-line concomitant EGFR-TKI + chemotherapy versus EGFR-TKI alone for advanced EGFR -mutated NSCLC: a meta-analysis of randomized phase III trials
1个月前
已完结
Management of adverse events related to first-generation tyrosine receptor kinase inhibitors in adults: a narrative review
1个月前
已完结
MET Alterations in Cancer and MET-Targeted Therapy: Detection Strategies, Treatment Efficacy, and Emerging Technologies
1个月前
已完结
Exploring 4th Generation EGFR Inhibitors: A Review of Clinical Outcomes and Structural Binding Insights
1个月前
已完结
皖公网安备34019202002308
